title: Independent factors predict supranormal CA 15-3 serum levels in advanced breast cancer patients at first disease relapse.
abstract: Data currently available are insufficient to demonstrate a real utility for CA 15-3 in the diagnosis, staging or surveillance of breast cancer patients following primary treatment. The aim of this study was to determine if there was a correlation between supranormal CA 15-3 serum levels and clinical and biological variables in breast cancer patients at first disease relapse. From October 1988 to March 1998, 430 consecutive patients entered the study. Overall CA 15-3 sensitivity was 60.7%. Elevated CA 15-3 levels were found more frequently in patients with liver metastases (74.6%) and in those with pleural effusion (75.7%). CA 15-3 sensitivity was 70.4% in patients with estrogen-receptor-positive (ER+) primary tumors and 45.9% in those with estrogen-receptor-negative (ER-) tumors (p < 0.0001). In patients with a limited extent of disease, marker sensitivity was 57.7% in ER+ tumors and 25.7% in ER- tumors (p < 0.0001). Logistic regression analysis showed ER status, disease extent and pleural effusion as independent variables associated with CA 15-3 positivity. The multivariate Cox analysis showed ER and disease extent as independent variables predicting overall survival, whereas CA 15-3 failed to be statistically significant. CA 15-3 was an independent variable only when the disease extent variable was removed. This study suggests that CA 15-3 in advanced breast cancer patients is a marker of both disease extent and ER status. The direct relationship with ER status indicates that CA 15-3 diagnostic sensitivity in the early detection of disease recurrence could be greater in ER+ patients than in ER- ones. Furthermore, this suggests that patients with elevated CA 15-3 levels could have disease that is more sensitive to hormone manipulation than those with normal CA 15-3 values.
authors.affiliation: Oncologia Medica, Dipartimento di Scienze Cliniche e Biologiche, Università di Torino, Azienda Ospedaliera San Luigi, Orbassano, Italia.
authors.forename: M
authors.initials: M
authors.lastname: Tampellini
authors.forename: A
authors.initials: A
authors.lastname: Berruti
authors.forename: G
authors.initials: G
authors.lastname: Gorzegno
authors.forename: R
authors.initials: R
authors.lastname: Bitossi
authors.forename: A
authors.initials: A
authors.lastname: Bottini
authors.forename: A
authors.initials: A
authors.lastname: Durando
authors.forename: A
authors.initials: A
authors.lastname: De Matteis
authors.forename: A
authors.initials: A
authors.lastname: Farris
authors.forename: M
authors.initials: M
authors.lastname: Donadio
authors.forename: E
authors.initials: E
authors.lastname: De Fabiani
authors.forename: E
authors.initials: E
authors.lastname: Manzin
authors.forename: P
authors.initials: P
authors.lastname: Arese
authors.forename: M G
authors.initials: MG
authors.lastname: Sarobba
authors.forename: F
authors.initials: F
authors.lastname: Castiglione
authors.forename: G
authors.initials: G
authors.lastname: Moro
authors.forename: G
authors.initials: G
authors.lastname: Bonazzi
authors.forename: F
authors.initials: F
authors.lastname: Nuzzo
authors.forename: M
authors.initials: M
authors.lastname: Massobrio
authors.forename: L
authors.initials: L
authors.lastname: Dogliotti
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood* / Q000473:pathology / Q000503:physiopathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D018396:Mucin-1 / Q000097:blood*; D015999:Multivariate Analysis; D011237:Predictive Value of Tests; D011379:Prognosis; D012008:Recurrence
chemical_list: D014408:Biomarkers, Tumor; D018396:Mucin-1